➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKesson
Moodys
Johnson and Johnson
Colorcon

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RAVIDASVIR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for Ravidasvir

Trial ID Title Status Sponsor Phase Summary
NCT02371408 A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 Active, not recruiting Pharco Pharmaceuticals Phase 2/Phase 3 The study will assess the efficacy of PPI-668 (USAN: ravidasvir hydrochloride) in combination with sofosbuvir, with or without ribavirin, in the following Egyptian HCV gt-4 patient populations: 1. Treatment-naïve patients, with and without cirrhosis (Group 1) 2. Previous non-responders to interferon-based therapies, without cirrhosis (Group 2) 3. Previous non-responders to interferon-based therapies, with cirrhosis (Group 3)
NCT02961426 Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection Recruiting Ministry of Health, Malaysia Phase 2/Phase 3 This is a Phase II/III, multicenter, multi-country, trial to assess the efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir for the treatment of HCV infection.
NCT02961426 Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection Recruiting Drugs for Neglected Diseases Phase 2/Phase 3 This is a Phase II/III, multicenter, multi-country, trial to assess the efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir for the treatment of HCV infection.
NCT03020095 Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan Active, not recruiting Ascletis Pharmaceuticals Co., Ltd. Phase 2 The purpose of this study is to evaluate the efficacy, safety and tolerability of Ravidasvir (ASC16) in combination with Ritonavir-boosted Danoprevir(ASC08) and Ribavirin in treatment-naive no-cirrhotic Taiwanese patients who have chronic hepatitis C genotype1.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Ravidasvir

Condition Name

Condition Name for
Intervention Trials
Chronic Hepatitis c 3
Healthy 3
HCV 1
Bioequivalence Study 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Hepatitis C 4
Hepatitis, Chronic 3
Hepatitis C, Chronic 3
Hepatitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ravidasvir

Trials by Country

Trials by Country for
Location Trials
China 4
Malaysia 2
Thailand 1
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ravidasvir

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2/Phase 3 3
Phase 2 1
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 4
Active, not recruiting 4
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ravidasvir

Sponsor Name

Sponsor Name for
Sponsor Trials
Ascletis Pharmaceuticals Co., Ltd. 6
Drugs for Neglected Diseases 2
Ministry of Health, Malaysia 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 7
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Medtronic
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.